A股異動 | 博騰股份漲逾4% 拿下2.17億美元大單 超去年營收50%
格隆匯12月1日丨博騰股份漲逾4%,報104.24元創逾兩個月新高,總市值567億元。博騰股份昨晚發佈一則重大訂單公吿,其中表示收到美國某大型製藥公司的新一批《採購訂單》,該等訂單為客户某小分子創新藥相關的合同定製研發生產(CDMO)服務訂單。截至訂單送達日,公司過去連續12個月內累計收到相關產品的訂單金額合計2.17億美元,超過公司最近一個會計年度經審計營業收入的50%。類似的訂單服務情況與保密條例等,與此前凱萊英(002821.SZ)公佈的新簽訂單幾乎完全一致,而此前凱萊英上述服務對象則被外界廣泛猜測為美國輝瑞,涉及產品為輝瑞的新冠口服藥Paxlovid。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.